http://www.medcitynews.com/2009/05/does-biotech-win-if-vcs-get-a-better-chance-at-sbir/?utm_source=rss&utm_medium=rss&utm_campaign=does-biotech-win-if-vcs-get-a-better-chance-at-sbir MedCity News Sat, 11 Feb 2012 15:17:29 +0000 hourly 1 http://wordpress.org/?v=3.2.1 http://www.medcitynews.com/2009/05/does-biotech-win-if-vcs-get-a-better-chance-at-sbir/comment-page-1/#comment-83737 Michael Squillante Thu, 01 Jul 2010 15:12:58 +0000 http://www.medcitynews.com/?p=4452#comment-83737 Federal rulings clarified and reinterpreted the participation of venture funded firms, they did not change the regulations and they did not exclude anyone. In fact, the rulings widened the legitimate participation of VC owned firms. Prior to that VC firms that were not "controlled" by a VC were allowed to participate and still are. The existing law at the time did not allow VC controlled firms to participate since they were not owned by an "individual" who was a US citizen. That many VC controlled firms did participate was a result of lax enforcement of the rules. The SBA rulings opened the door to firms that were less than 50% "owned" by VCs (rather than controlled by VCs) and allowed participation firms that were owned by small VC firms, which was not allowed prior to the rulings. Michael Squillante, Chairman SBTC Federal rulings clarified and reinterpreted the participation of venture funded firms, they did not change the regulations and they did not exclude anyone. In fact, the rulings widened the legitimate participation of VC owned firms. Prior to that VC firms that were not “controlled” by a VC were allowed to participate and still are. The existing law at the time did not allow VC controlled firms to participate since they were not owned by an “individual” who was a US citizen. That many VC controlled firms did participate was a result of lax enforcement of the rules. The SBA rulings opened the door to firms that were less than 50% “owned” by VCs (rather than controlled by VCs) and allowed participation firms that were owned by small VC firms, which was not allowed prior to the rulings.
Michael Squillante, Chairman SBTC

]]> http://www.medcitynews.com/2009/05/does-biotech-win-if-vcs-get-a-better-chance-at-sbir/comment-page-1/#comment-12462 MedCity News: The minds of Midwest VCs: Reform, commercialization czars and beware the gullible angel investor | DIALED-IN Mon, 03 Aug 2009 19:13:09 +0000 http://www.medcitynews.com/?p=4452#comment-12462 [...] Kleinhenz, of CID Capital Partners, on SBIR reform that could give venture-backed firms more federal dollars: “Legislative people have to get over the bogeyman — we’re not the bogeyman. We don’t do R [...] [...] Kleinhenz, of CID Capital Partners, on SBIR reform that could give venture-backed firms more federal dollars: “Legislative people have to get over the bogeyman — we’re not the bogeyman. We don’t do R [...]

]]> http://www.medcitynews.com/2009/05/does-biotech-win-if-vcs-get-a-better-chance-at-sbir/comment-page-1/#comment-12236 The minds of Midwest VCs: Reform, commercialization czars and beware the gullible angel investor : MedCity News Fri, 31 Jul 2009 17:06:51 +0000 http://www.medcitynews.com/?p=4452#comment-12236 [...] Kleinhenz, of CID Capital Partners, on SBIR reform that could give venture-backed firms more federal dollars: “Legislative people have to get over the bogeyman — we’re not the bogeyman. We [...] [...] Kleinhenz, of CID Capital Partners, on SBIR reform that could give venture-backed firms more federal dollars: “Legislative people have to get over the bogeyman — we’re not the bogeyman. We [...]

]]> http://www.medcitynews.com/2009/05/does-biotech-win-if-vcs-get-a-better-chance-at-sbir/comment-page-1/#comment-8068 Two bills to renew SBIR program clash on venture capital inclusion — MedCity Morning Read, June 29, 2009 : MedCity News Mon, 29 Jun 2009 12:22:58 +0000 http://www.medcitynews.com/?p=4452#comment-8068 [...] Life sciences interests have largely supported expanding SBIR/STTR funding to include venture-backed companies. However, some smaller biotech companies — especially Midwest companies that tend to get less venture capital investment than those in New York and California — see the expansion as a potential death knell for small business and innovation funding. [...] [...] Life sciences interests have largely supported expanding SBIR/STTR funding to include venture-backed companies. However, some smaller biotech companies — especially Midwest companies that tend to get less venture capital investment than those in New York and California — see the expansion as a potential death knell for small business and innovation funding. [...]

]]> http://www.medcitynews.com/2009/05/does-biotech-win-if-vcs-get-a-better-chance-at-sbir/comment-page-1/#comment-7121 Senate legislation expands SBIR, VC-firms win some access : MedCity News Fri, 19 Jun 2009 17:49:38 +0000 http://www.medcitynews.com/?p=4452#comment-7121 [...] 2009 (pdf) may actually be an acceptable compromise for many – including those in biotech – who worried about how much money companies owned mostly by VCs could [...] [...] 2009 (pdf) may actually be an acceptable compromise for many – including those in biotech – who worried about how much money companies owned mostly by VCs could [...]

]]> http://www.medcitynews.com/2009/05/does-biotech-win-if-vcs-get-a-better-chance-at-sbir/comment-page-1/#comment-3791 Does biotech win if VCs get a better chance at SBIR? | DIALED-IN Thu, 28 May 2009 15:37:29 +0000 http://www.medcitynews.com/?p=4452#comment-3791 [...] Via MedCity News [...] [...] Via MedCity News [...]

]]>